Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Shuntaro, Obi"'
Autor:
Hideo Yoshida, Takamasa Ohki, Mineo Kanezaki, Takuma Teratani, Shinpei Sato, Shuntaro Obi, Takahisa Sato, Masatoshi Akamatsu, Koji Uchino, Hiroyoshi Taniguchi
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background Platelet (PLT) transfusion was the most practical way to increase patients’ PLT counts before invasive hepatic procedures such as radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). A novel drug that raises the PLT
Externí odkaz:
https://doaj.org/article/4a7c05d198684aea80a2465f63aec9b7
Autor:
Tatsuya Minami, Ryosuke Tateishi, Naoto Fujiwara, Ryo Nakagomi, Takuma Nakatsuka, Masaya Sato, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Hidetaka Fujinaga, Masashi Izumiya, Kazuyuki Hanajiri, Yoshinari Asaoka, Yuji Kondo, Yasuo Tanaka, Motoyuki Otsuka, Takamasa Ohki, Masahiro Arai, Atsushi Tanaka, Kiyomi Yasuda, Hideaki Miura, Itsuro Ogata, Toshiro Kamoshida, Kazuaki Inoue, Yukihiro Koike, Masatoshi Akamatsu, Hiroshi Mitsui, Hajime Fujie, Keiji Ogura, Hideo Yoshida, Tomonori Wada, Kiyohiko Kurai, Hisato Maekawa, Shuntaro Obi, Takuma Teratani, Naohiko Masaki, Kayo Nagashima, Takashi Ishikawa, Naoya Kato, Kyoji Moriya, Hiroshi Yotsuyanagi, Kazuhiko Koike
Publikováno v:
Liver Cancer, Pp 1-11 (2021)
Background and Aims: It remains unclear whether obesity increases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C who achieved a sustained virological response (SVR) with antiviral therapy. Methods: In this multicenter
Externí odkaz:
https://doaj.org/article/a624671861264ea39d61aa7dc2a09d39
Autor:
Kazuomi Ueshima, Atsushi Komemushi, Takeshi Aramaki, Hideki Iwamoto, Shuntaro Obi, Yozo Sato, Toshihiro Tanaka, Kiyoshi Matsueda, Michihisa Moriguchi, Hiroya Saito, Miyuki Sone, Takuji Yamagami, Yoshitaka Inaba, Masatoshi Kudo, Yasuaki Arai
Publikováno v:
Liver Cancer (2022)
Hepatocellular carcinoma is one of the leading causes of cancer-related death not only in Japan, but also worldwide. In the advanced stage, hepatic arterial infusion chemotherapy (HAIC) is one of the most commonly used treatment options for liver can
Externí odkaz:
https://doaj.org/article/ed71cd65a3114b42a79742439cfd20d9
Autor:
Takamasa Ohki, Koki Sato, Mayuko Kondo, Eriko Goto, Takahisa Sato, Yuji Kondo, Masatoshi Akamatsu, Shinpei Sato, Hideo Yoshida, Yukihiro Koike, Shuntaro Obi
Publikováno v:
Liver Research, Vol 4, Iss 4, Pp 199-205 (2020)
Background and aims: Lenvatinib (LEN) is a newly developed tyrosine kinase inhibitor, and is approved as a first-line treatment for advanced hepatocellular carcinoma (HCC) in Japan. This retrospective multi-center study investigated the effect of the
Externí odkaz:
https://doaj.org/article/49123965d8f046a6b238f35da0fd3112
Autor:
Kazuomi Ueshima, Sadahisa Ogasawara, Masafumi Ikeda, Yutaka Yasui, Takeshi Terashima, Tatsuya Yamashita, Shuntaro Obi, Shinpei Sato, Hiroshi Aikata, Takumi Ohmura, Hidekatsu Kuroda, Takamasa Ohki, Kengo Nagashima, Yoshihiko Ooka, Masahiro Takita, Masayuki Kurosaki, Kazuaki Chayama, Shuichi Kaneko, Namiki Izumi, Naoya Kato, Masatoshi Kudo, Masao Omata
Publikováno v:
Liver Cancer, Pp 1-13 (2020)
Background: Prior to the approval of sorafenib, hepatic arterial infusion chemotherapy (HAIC) was offered to patients with advanced hepatocellular carcinoma (HCC) in East Asia, particularly Japan. According to the Japanese guidelines, HAIC is recomme
Externí odkaz:
https://doaj.org/article/ef5cfbd8fe554dd99240bb3311551d66
Autor:
Takamasa Ohki, Koki Sato, Mayuko Kondo, Eriko Goto, Takahisa Sato, Yuji Kondo, Masatoshi Akamatsu, Shinpei Sato, Hideo Yoshida, Yukihiro Koike, Shuntaro Obi
Publikováno v:
Drugs - Real World Outcomes, Vol 7, Iss 2, Pp 141-149 (2020)
Abstract Background and Objective Experience of the use of lenvatinib (LEN) in the clinical setting remains limited. We conducted this study to elucidate the factors associated with progression-free survival (PFS) in patients with advanced HCC treate
Externí odkaz:
https://doaj.org/article/a0fbba4ad7974a68962730adec11987e
Autor:
Shuntaro Obi, Miho Kanda, Yoshihiko Ooka, Hiroshi Ohyama, Ritsuko Yokouchi, Naho Sato, Hitoshi Mochizuki, Masao Omata
Publikováno v:
Hepatology International. 17:562-572
Autor:
Hiroyuki Amano, Tatsuo Kanda, Hitoshi Mochizuki, Yuichiro Kojima, Yoji Suzuki, Kenji Hosoda, Hiroshi Ashizawa, Yuko Miura, Shotaro Tsunoda, Yosuke Hirotsu, Hiroshi Ohyama, Naoya Kato, Mitsuhiko Moriyama, Shuntaro Obi, Masao Omata
Publikováno v:
Viruses, Vol 13, Iss 11, p 2216 (2021)
Hepatitis B virus (HBV) infection is one of the serious health problems in the world as HBV causes severe liver diseases. Moreover, HBV reactivation has occasionally been observed in patients with resolved HBV infection and patients using immunosuppr
Externí odkaz:
https://doaj.org/article/39b5397846db4ef8aef95e73fdbb60e9
Autor:
Takashi Murakami, Hiroaki Shimizu, Kazuto Yamazaki, Hiroyuki Nojima, Akihiro Usui, Chihiro Kosugi, Kiyohiko Shuto, Shuntaro Obi, Takahisa Sato, Masato Yamazaki, Keiji Koda
Publikováno v:
World Journal of Clinical Cases. 10:8709-8717
Autor:
Hideo Yoshida, Takamasa Ohki, Mineo Kanezaki, Takuma Teratani, Shinpei Sato, Shuntaro Obi, Takahisa Sato, Masatoshi Akamatsu, Koji Uchino, Hiroyoshi Taniguchi
Background Platelet (PLT) transfusion was the most practical way to increase patients’ PLT counts before invasive hepatic procedures such as radiofrequency ablation (RFA) for liver cancer. A novel drug that raises the PLT count by acting on the thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b289a443a10443329a49548bacf73c8
https://doi.org/10.21203/rs.3.rs-2423711/v1
https://doi.org/10.21203/rs.3.rs-2423711/v1